Imeglimin population pharmacokinetics and dose adjustment predictions for renal impairment in Japanese and Western patients with type 2 diabetes

Imeglimin is an orally administered first‐in‐class drug to treat type 2 diabetes mellitus (T2DM) and is mainly excreted unchanged by the kidneys. The present study aimed to define the pharmacokinetic (PK) characteristics of imeglimin using population PK analysis and to determine the optimal dosing r...

Descripción completa

Detalles Bibliográficos
Autores principales: Tomita, Yoshiko, Hansson, Emma, Mazuir, Florent, Wellhagen, Gustaf J, Ooi, Qing Xi, Mezzalana, Enrica, Kitamura, Atsushi, Nemoto, Daisuke, Bolze, Sébastien
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9010270/
https://www.ncbi.nlm.nih.gov/pubmed/34962074
http://dx.doi.org/10.1111/cts.13221

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9010270/
https://www.ncbi.nlm.nih.gov/pubmed/34962074
http://dx.doi.org/10.1111/cts.13221

Ejemplares similares